CN113518776A - 苯并噻吩类化合物及其制备方法和用途 - Google Patents

苯并噻吩类化合物及其制备方法和用途 Download PDF

Info

Publication number
CN113518776A
CN113518776A CN202080017726.XA CN202080017726A CN113518776A CN 113518776 A CN113518776 A CN 113518776A CN 202080017726 A CN202080017726 A CN 202080017726A CN 113518776 A CN113518776 A CN 113518776A
Authority
CN
China
Prior art keywords
compound
cycloalkyl
group
alkyl
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080017726.XA
Other languages
English (en)
Other versions
CN113518776B (zh
Inventor
刘金明
任云
田强
宋宏梅
薛彤彤
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN113518776A publication Critical patent/CN113518776A/zh
Application granted granted Critical
Publication of CN113518776B publication Critical patent/CN113518776B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Figure DDA0003236960830000011
本发明涉及式I的化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N‑氧化物、同位素标记的化合物、代谢物或前药，包含其的药物组合物和药盒，其制备方法及其在制备用于预防或治疗STING介导的相关疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN202080017726.XA 2019-04-30 2020-04-20 苯并噻吩类化合物及其制备方法和用途 Active CN113518776B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910359616 2019-04-30
CN2019103596160 2019-04-30
PCT/CN2020/085525 WO2020221038A1 (zh) 2019-04-30 2020-04-20 苯并噻吩类化合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN113518776A true CN113518776A (zh) 2021-10-19
CN113518776B CN113518776B (zh) 2024-03-26

Family

ID=73028761

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080017726.XA Active CN113518776B (zh) 2019-04-30 2020-04-20 苯并噻吩类化合物及其制备方法和用途

Country Status (6)

Country Link
US (1) US20220162199A1 (zh)
EP (1) EP3964504A4 (zh)
JP (1) JP2022530936A (zh)
KR (1) KR20220004013A (zh)
CN (1) CN113518776B (zh)
WO (1) WO2020221038A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023036195A1 (zh) * 2021-09-08 2023-03-16 上海交通大学 一类含有氘取代的苯并噻吩类衍生物及其制备与用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026009A1 (en) 2019-08-02 2021-02-11 Mersana Therapeutics, Inc. Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
EP4069683A1 (en) * 2019-12-06 2022-10-12 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
WO2023211940A1 (en) * 2022-04-25 2023-11-02 The Regents Of The University Of Michigan Sting agonists, formulations, and uses thereof
WO2024032782A1 (en) * 2022-08-12 2024-02-15 Jacobio Pharmaceuticals Co.Ltd. Vaccine adjuvants and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1835943A (zh) * 2003-01-14 2006-09-20 阿伦纳药品公司 作为代谢调节剂的1,2,3－三取代的芳基和杂芳基衍生物以及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
WO2018067423A1 (en) * 2016-10-04 2018-04-12 Merck Sharp & Dohme Corp. BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
WO2018234805A1 (en) * 2017-06-22 2018-12-27 Curadev Pharma Limited SMALL MOLECULAR MODULATORS OF HUMAN STING
WO2018234808A1 (en) * 2017-06-22 2018-12-27 Curadev Pharma Limited MODULATORS WITH SMALL MOLECULES OF STING HUMAIN
WO2019027857A1 (en) * 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER
WO2019027858A1 (en) * 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. BENZO [B] STING THIOPHEN AGONISTS FOR THE TREATMENT OF CANCER
CN109563081A (zh) * 2016-04-07 2019-04-02 葛兰素史克知识产权开发有限公司 可用作蛋白调节剂的杂环酰胺类
WO2019069275A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited STING AGONIST ADMINISTRATION METHODS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5539868B2 (ja) * 2007-07-18 2014-07-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｍ８モジュレーターとしてのスルホンアミド類
US20200172483A1 (en) 2017-06-22 2020-06-04 Curadev Pharma Limited Heterocyclic small molecule modulators of human sting

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1835943A (zh) * 2003-01-14 2006-09-20 阿伦纳药品公司 作为代谢调节剂的1,2,3－三取代的芳基和杂芳基衍生物以及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
CN109563081A (zh) * 2016-04-07 2019-04-02 葛兰素史克知识产权开发有限公司 可用作蛋白调节剂的杂环酰胺类
WO2018067423A1 (en) * 2016-10-04 2018-04-12 Merck Sharp & Dohme Corp. BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
WO2018234805A1 (en) * 2017-06-22 2018-12-27 Curadev Pharma Limited SMALL MOLECULAR MODULATORS OF HUMAN STING
WO2018234808A1 (en) * 2017-06-22 2018-12-27 Curadev Pharma Limited MODULATORS WITH SMALL MOLECULES OF STING HUMAIN
WO2019027857A1 (en) * 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER
WO2019027858A1 (en) * 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. BENZO [B] STING THIOPHEN AGONISTS FOR THE TREATMENT OF CANCER
WO2019069275A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited STING AGONIST ADMINISTRATION METHODS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
路倩颖 等: ""cGAS-STING信号通路和疾病"", 《国际生物医学工程杂志》, vol. 39, no. 6, pages 368 - 375 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023036195A1 (zh) * 2021-09-08 2023-03-16 上海交通大学 一类含有氘取代的苯并噻吩类衍生物及其制备与用途

Also Published As

Publication number Publication date
US20220162199A1 (en) 2022-05-26
WO2020221038A1 (zh) 2020-11-05
KR20220004013A (ko) 2022-01-11
EP3964504A4 (en) 2022-12-28
CN113518776B (zh) 2024-03-26
EP3964504A1 (en) 2022-03-09
JP2022530936A (ja) 2022-07-05

Similar Documents

Publication Publication Date Title
CN113518776A (zh) 苯并噻吩类化合物及其制备方法和用途
CN109983007B (zh) 酰胺类衍生物抑制剂及其制备方法和应用
JP5820921B2 (ja) １，２−二置換複素環式化合物
ES2833576T3 (es) Inhibidores de glutaminasa novedosos
WO2020094104A1 (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
CN112442013B (zh) 一种作为甲状腺激素β受体激动剂的化合物及其用途
JP2003522773A (ja) 血管形成および／またはｖｅｇｆ受容体チロシンキナーゼを阻害するピリジン誘導体
CN115884969A (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN112661754B (zh) 一类抑制rna解旋酶dhx33的多环化合物
EP3845527A1 (en) Multi-substituted pyridone derivatives and medical use thereof
KR20130130071A (ko) 퀴놀리논 유도체
CA3143334A1 (en) Glycolate oxidase inhibitors for the treatment of disease
JP2022542162A (ja) ヘテロ環式アミド化合物及びその製造方法並びに使用
JP2023527242A (ja) Ａｘｌ阻害剤であるピリミジン系化合物
CN115536648A (zh) 一类抑制rna解旋酶dhx33的多环化合物及其应用
TW202321263A (zh) 磺醯胺衍生物、其製備方法及其在醫藥上的應用
CN112574191B (zh) 异噁唑杂环类化合物及其应用
CN111848572B (zh) 酰胺类化合物及其制备方法和用途
CN113045551A (zh) 一种作为甲状腺激素β受体激动剂的化合物及其用途
AU2016314355A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
CN111848573B (zh) 苯并噻吩酰胺类化合物及其制备方法和用途
CN111630047A (zh) 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
WO2023030335A1 (zh) 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法
WO2022063333A1 (zh) 一种嘧啶甲酰胺类化合物及其应用
CA3197220A1 (en) 2-pyridones as thyroid hormone receptor modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40061190

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant